Modifiable risk and protective factors for boosting brain and cognitive development and
preventing neurodegeneration and cognitive decline are embraced in neuroimaging …

In an ever-increasing aged world, Alzheimer's disease (AD) represents the first cause of
dementia and one of the first chronic diseases in elderly people. With 55 million people …

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …

Importance Antiamyloid immunotherapies against Alzheimer disease (AD) are emerging.
Scalable, cost-effective tools will be needed to identify amyloid β (Aβ)–positive patients …

Background The arrival of new disease-modifying treatments for Alzheimer's disease (AD)
requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way …

Catalytic hairpin assembly (CHA) is a promising enzyme-free, isothermal signal
amplification strategy, but the relatively time-consuming strand replacement limits its …

Background and objective Phosphorylated tau (p-tau) 217 has recently received attention
because it seems more reliable than other p-tau variants for identifying Alzheimer's disease …

Background Blood-based biomarkers of Alzheimer's disease (AD) have become
increasingly important as scalable tools for diagnosis and determining clinical trial eligibility …

Over the past two decades, increased research has highlighted the connection between
endosomal trafficking defects and neurodegeneration. The endo-lysosomal network is an …